In the Phase IIb tumour-agnostic JAVELIN BRCA/ATM study evaluating the same combination, durable responses were more common in BRCA-associated tumour types (including breast and ovarian cancers) than other tumour types, but the confirmed ORR of 26% was below the pre-specified 40% threshold [52]. This evidence concerns the gene ATM and ovarian carcinoma.